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The precise  onset  of  adrenocortical  function has not  been 
defined, either by steroid secretion or expression profile of the 
biosynthetic  enzymes  (Figure  1).  By  immunohistochemistry 


















































Steroidogenic pathways involving the human adrenal cortex. De novo 
cortisol biosynthesis is shown in black; other pathways are in gray. DHEA, 
dehydroepiandrosterone; DHEAS, DHEA sulfate; ST, sulfotransferase.
Figure 2
Growth and vascular development of the human 
early fetal adrenal gland. (A) Relative proportion 
of adrenal gland (ADR) to kidney (KID) during 
early development. (B) Weight (± SEM) of indi-
vidual adrenal glands and developmental age. (C 
and D) Brightfield IHC with anti-CD34 to dem-
onstrate vascular development counterstained 
by toluidine blue at 41 (C) and 50 (D) dpc. An 
adjacent H&E section is shown at the left of C. 
ac, adrenal cortex; ao, aorta; c, capsule; mg, 
mesonephric glomerulus. Scale bars: 1 mm (A), 
300 mm (C and D).
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Steroidogenic enzyme and StAR expression in the developing human adrenal gland. Brightfield IHC at sequential developmental ages counter-
stained by toluidine blue with antibodies to StAR (A–E), CYP11A (F–J), CYP17 (K–O), CYP21 (P–T), and CYP11B1/CYP11B2 (U–Y). Dotted 
ring in A illustrates extent of the adrenal cortex in left panels (A, F, K, P, and U). In other images, the definitive zone (DZ) is oriented to the left 
and the fetal zone (FZ) to the right. At 14 wpc, these 2 zones were separated by an additional transitional zone (TZ). Scale bar: 300 mm.
Figure 4
HSD3B and NGFI-B immunoreactivity in the developing human adrenal gland. Brightfield IHC with antibodies to HSD3B (A–F) and NGFI-B (G–L) 
counterstained with toluidine blue. Dotted rings in A and G illustrate extent of the adrenal cortex. In other images, the definitive zone is oriented to 
the left and fetal zone to the right. Scale bar: 300 mm.
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RT-PCR analysis of adrenocortical enzymes and StAR at 8 wpc. 
(A) RT followed by 22 and 28 cycles of PCR for transcripts encod-
ing steroidogenic enzymes. (B) Specific identification of HSD3B2 
and HSD3B1 isoforms in the presence (+) and absence (–) of RT. 
No HSD3B1 transcript was detected in the adrenal sample after 42 
cycles of PCR. Positive controls were fetal testis (HSD3B2) and skin 
(HSD3B1); negative controls were H2O and genomic DNA (G).
Figure 6
Cortisol content and secretion from 
the early human adrenal cortex. (A) 
Cortisol content (mean ± SEM) per 
mg adrenal tissue at 8, 9, and 10 
wpc, with 8 wpc kidney as control. 
(B) Cortisol secretion (mean ± SEM) 
of paired adrenal glands stimulated 
by 10 mM forskolin at 8, 9, and 10 
wpc. (C) Cortisol secretion (mean 
± SEM) of paired adrenal glands at 
8 wpc in response to varying doses 
of ACTH(1–24). Statistical analyses 
of stimulated secretion compared to 
basal secretion achieved the same 
level of significance (***P < 0.005) 
for each ACTH dose. *P < 0.05; 
**P < 0.02. (D) PCR amplification 
of type 2 melanocortin receptor 
(MC2R) in the presence (+) and 
absence (–) of RT in the adrenal 
gland, testis, and ovary at 8 wpc 
with GAPDH control.
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ACTH secretion in vitro from the anterior pituitary at 8 wpc
ACTH content
Control < 1.1 pmol/l/16 h
Basal 410 ± 7.4 pmol/l/16 h
Inhibition by dexamethasone
5 nM 32.34% ± 13.0%
1 mM 51.9% ± 2.5%
Control, media alone; Basal, after overnight culture of anterior pituitary. 
Percentage decrease in media ACTH upon exposure to dexametha-
sone was standardized against untreated anterior pituitary explant. 
Normal upper limit of circulating ACTH in human adults is ~9 pmol/l. 
Results shown as mean ± SEM from at least 2 experiments.
Figure 7
Human early anterior pituitary development. (A) Sagittal section from 
head at 50 dpc. Pound symbol indicates oral cavity. (B–D) Bright-
field IHC with antibodies to ACTH (B and D) and GR (C) counter-
stained by toluidine blue. B and C show higher-magnification views 
of boxed region in A. Arrows show overlapping expression profiles of 
cytoplasmic ACTH and nuclear GR in adjacent sections. (D) Anterior 
pituitary at 8 wpc. bs, basosphenoid bone; h, developing hypothala-
mus; rp, Rathke’s pouch; t, tongue. Scale bars: 500 mm (A), 100 mm 
(B and C), 200 mm (D).
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Adrenal secretion of androstenedione and testosterone at 8 wpc
 Mean ± SEM Fold increase P
Androstenedione secretion
Basal 29.3 ± 2.77 nmol/l – –
Forskolin 117 ± 13.5 nmol/l 4.00 ± 0.11 < 0.005
ACTH 35.0 ± 1.73 nmol/l 1.20 ± 0.03 < 0.05
DEX 22.9 ± 3.40 nmol/l 0.78 ± 0.08 NS
Testosterone production
Basal 1.15 ± 0.10 nmol/l – –
Forskolin 3.33 ± 0.33 nmol/l 2.90 ± 0.29 < 0.002
ACTH 2.50 ± 0.10 nmol/l 2.17 ± 0.09 < 0.001
DEX 1.05 ± 0.23 nmol/l 0.91 ± 0.20 NS
Androstenedione and testosterone were not detected in control media. 
The response to 10 mM forskolin, 100 nM ACTH(1–24), and 1 mM dexa-
methasone (DEX) was tested.
Figure 8
Virilization of the external genitalia and adrenal androgen biosynthesis. 
(A) Undifferentiated human external genitalia at 8 wpc. (B) Male differ-
entiation of scrotal folds and fusion of the urethral folds (asterisks mark 
patent regions, either side) at 10 wpc. gs, genital swelling; gt, genital 
tubercle; sf, scrotal folds; uf, urethral folds. Scale bars: 500 mm. (C) 
PCR (35 cycles) in the presence (+) or absence (–) of RT for HSD17B 
isoforms known to convert androstenedione to testosterone. HSD17B5 
is also known as AKR1C3.
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Primary antibody Raised in Dilution Source and/or ref.
Polyclonal anti-StAR Sheep 1:3,000 (28)
Polyclonal anti-CYP11A Rabbit 1:1,500 Gift from A. Payne (Stanford University, 
   Stanford, California, USA; refs. 29, 30)
Polyclonal anti-CYP17 Rabbit 1:1,000 (10, 31, 32)
Polyclonal anti-HSD3B Rabbit 1:500 (33, 34, 35)
Polyclonal anti-CYP21 Rabbit 1:7,500 Gift from B.-C. Chung (University of Taipei, 
   Taipei, Republic of China; ref. 36)
Polyclonal anti-CYP11B1/2 Rabbit 1:500 Gift from H. Takemori and M. Okamoto (Osaka University 
   School of Medicine, Osaka, Japan)
Monoclonal anti-ACTH Mouse 1:1,000 Neomarkers
Monoclonal anti-GR Mouse 1:20 Alexis Corp.
Monoclonal anti-CD34 Mouse 1:50 Novocastra Ltd.
Monoclonal anti-CK19 Mouse 1:100 Novocastra Ltd.
Monoclonal anti-Ki67 Mouse 1:200 Novocastra Ltd.
Polyclonal anti–NGFI-B Rabbit 1:200 Geneka Biotechnology Inc. (8)
 
Figure 9
Schematic diagram of human early adrenal function and its implica-
tions for androgen-mediated development.
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